Highlights from 2024 Thai Guidelines on the Treatment of Hypertension by the Thai Hypertension Society and Intensive Blood Pressure Control to Reduce the Risk of Cardiovascular Disease in the Future
Keywords:
Hypertension, Intensive blood pressure control, Cardiovascular diseaseAbstract
Hypertension is a common condition in the Thai population, affecting up to 14 million people. Increases in blood pressure levels increase the risk of death from cardiovascular disease and stroke. Therefore, hypertension is a condition that is significant to the Thai public health system. As a result, the Thai Hypertension Society has consistently created guidelines for managing hypertension in clinical settings, with the most recent version being 2024, aimed at the early detection of high blood pressure. Diagnosed when blood pressure levels are >140/90 mmHg in general, including blood pressure in the risk group >130/80 mmHg, along with the identification of hypertension-mediated organ damage, Patients ought to be diagnosed with hypertension when it is determined that the blood pressure recorded at the hospital aligns with the standards for diagnosing hypertension from being examined more than once. To manage hypertension, it is advised to implement lifestyle modification and utilize the required medication. Taking two different types of drugs from each of the five main drug groups at the same time is generally recommended and use two types of drugs in one pill if possible. And establish suitable treatment objectives based on age and risk. In general, in the population of 18-64 years, blood pressure levels <130/80 mm Hg, etc., and there is new research data, there is a tendency to intensive blood pressure control, blood pressure levels <120/80 (120-129/70-79) mm Hg in groups with high risk of cardiovascular disease. This article introduces the 2024 Thai Guidelines for Hypertension Management that have been created by the Thai Hypertension Society. These guidelines gather the evidence pertaining to the impacts of hypertension treatment.
References
Thai Hypertension Society. Thai Hypertension Society: Guidelines in the Treatment of Hypertension 2019. Bangkok: Trick Think; 2019.
Kunanon S, Roubsanthisuk W, Chattranukulchai P, Sangwatanaroj S, Ophascharoensuk V, Sitthisook S, et al. 2022 Thai Hypertension Society guidelines on home blood pressure monitoring. J Clin Hypertens (Greenwich) 2022;24(9):1139-46.
Thai Hypertension Society. Thai Hypertension Society: Guidelines in the Treatment of Hypertension 2024. Bangkok: Trick Think; 2024.
National Drug Policy Division. Thailand’s National List of Essential Medicines (NLEM) 2026. [Internet] 2026 [cited 2026]. Available from: https://ndp.fda.moph.go.th/
SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373(22):2103-16.
Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med 2021;385(14):1268-79.
Liu J, Li Y, Ge J, Yan X, Zhang H, Zheng X, et al. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet 2024;404(10449):245-55.
Bi Y, Li M, Liu Y, Li T, Lu J, Duan P, et al. Intensive blood-pressure control in patients with type 2 diabetes. N Engl J Med 2025;392(12):1155-67.
McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 2024;45(38):3912-4018.
Whelton PK, O’Connell S, Mills KT, He J. Optimal antihypertensive systolic blood pressure: a systematic review and meta-analysis. Hypertension 2024;81(11):2329-39.
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360(9349):1903-13.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Department of Medical Services, Ministry of Public Health

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความที่ได้รับการตีพิมพ์เป็นลิขสิทธิ์ของกรมการแพทย์ กระทรวงสาธารณสุข
ข้อความและข้อคิดเห็นต่างๆ เป็นของผู้เขียนบทความ ไม่ใช่ความเห็นของกองบรรณาธิการหรือของวารสารกรมการแพทย์